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ABSTRACT 
Extracellular vesicles (EV), which include exosomes and microvesicles, are secreted 
from virtually every cell. EV contain mRNA, miRNA, lipids and proteins and can 
deliver this expansive cargo into nearby cells as well as over long distances via the 
blood stream. Great interest has been given to them for their role in cell to cell 
communication, disease progression, or as biomarkers, and more recent studies 
have interrogated their potential as a therapeutic that may replace paracrine-acting 
cell therapies. The retina is a conveniently accessible component of the central 
nervous system and the proposed paradigm for the testing of many cell therapies. 
Recently, several studies have been published demonstrating that the delivery of 
EV/exosomes into the eye can elicit significant therapeutic effects in several models 
of retinal disease. We summarize results from currently available studies, 
demonstrating their efficacy in multiple eye disease models as well as highlighting 
where future research efforts should be directed. 
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1. Introduction 1 
The retina, due to its diencephalic origin, is part of the central nervous system (CNS) 2 
and converts photons into an electrochemical signal in a process known as 3 
phototransduction, allowing organisms to see. As typical with the CNS, damage, 4 
which can arise through a variety of traumatic and degenerative reasons, is 5 
permanent alongside the subsequent visual loss (Berry et al., 2019; Berry et al., 6 
2008). Retinal diseases have multiple (non-mutually exclusive) theories explaining 7 
their cause and progression, owing to their complicated and multifactorial nature. It 8 
can be argued that a successful therapy must consider these multiple mechanisms 9 
rather than focusing on one pathway or molecule. In the example of glaucomatous 10 
damage, the majority of studies and pre-clinical therapies however target just one 11 
particular mechanism or signaling pathway e.g. glutamate-mediated excitotoxicity, 12 
tumor necrosis factor-α (TNF-α)-mediated inflammation, neurotrophic factor (NTF) 13 
deprivation etc. Several combinatorial therapies have been devised to address the 14 
multifactorial nature of retinal disease, from the literal combination and delivery of 15 
multiple NTF (Logan et al., 2006) to cellular therapy, whereby transplanted 16 
mesenchymal/neural stem cells (MSC/NSC) secrete a combination of said NTF 17 
(Flachsbarth et al., 2018; Johnson et al., 2014; Lu et al., 2013; Mead et al., 2015; 18 
Mead et al., 2014; Mesentier-Louro et al., 2014) and anti/pro-inflammatory cytokines 19 
(Millan-Rivero et al., 2018; Uccelli et al., 2008). Our earlier studies demonstrated the 20 
potential for MSC (bone marrow- and dental pulp-derived) transplantation in a model 21 
of glaucoma (Johnson et al., 2010a; Mead et al., 2016), with significant 22 
neuroprotection of degenerating retinal ganglion cells (RGC) observed. MSC 23 
remained in the vitreous with their therapeutic efficacy resulting from paracrine-24 
mediated mechanisms (Fig. 1). 25 
However, another secreted product of MSC that is suggested to mediate the 26 
paracrine benefit has recently gained a large amount of research interest. Known as 27 
extracellular vesicles (EV), their strong therapeutic potential derives from their 28 
expansive cargo and ability to deliver said cargo into cells and act on multiple 29 
signaling pathways (Kalluri and LeBleu, 2020). EV are becoming established 30 
signaling mediators between cells, including in the eye (Reviewed in Klingeborn et 31 
al., 2017a), but only recently are they gaining traction as a candidate treatment for 32 
ocular disease. This review discusses current progress in utilizing EV as a therapy 33 
for retinal diseases. 34 
 35 
2. Extracellular Vesicles 36 
EV is the collective term for secreted vesicles and includes exosomes, 37 
microvesicles, and apoptotic bodies. They have distinct biogenesis pathways (Fig. 2) 38 
and are often distinguished by their size, internal cargo, and surface proteins. 39 
Exosomes form via the fusion of multivesicular bodies (an intracellular vesicular 40 
structure derived from endosomes) with the cell membrane and their subsequent 41 
release into the extracellular space (Mathieu et al., 2019; Thery et al., 2006). 42 
Microvesicles are instead formed due to outward budding of the plasma membrane. 43 
Exosomes are typically 30-150 nm whereas microvesicles are 100-1000 nm, 44 
although the exact values vary greatly between studies. Analysis of their size can be 45 
done using electron microscopy (Osteikoetxea et al., 2015) or a nanoparticle tracking 46 
analysis instrument (Fig. 3).The third class of EV, apoptotic bodies, are >1000nm 47 
and are released through the membrane blebbing of cells undergoing apoptosis 48 
(Battistelli and Falcieri, 2020; Caruso and Poon, 2018; Jiang et al., 2017), although 49 
smaller EV from apoptotic cells (termed apoptotic microvesicles) have also been 50 
suggested. Apoptotic bodies have so far not seen any therapeutic use in the eye and 51 
appear to mainly function as signals to recruit macrophages to aid in cell debris 52 
clearing, as well as antigen presentation(Caruso and Poon, 2018). They do however 53 
contain miRNA and proteins as well as represent a heterogeneous population of 54 
subtypes and further study into their therapeutic and/or deleterious effects should be 55 
explored. In contrast, exosomes have shown remarkable therapeutic potential in 56 
many diseases throughout the body (Reviewed in Keshtkar et al., 2018) including 57 
Alzheimer’s disease (de Godoy et al., 2018), spinal cord injury (Sun et al., 2018; 58 
Wang et al., 2018a) and stroke (Xin et al., 2013; Xin et al., 2017), amongst others. 59 
Despite these differing subpopulations of EV, much overlap exists in the literature, 60 
with the term “exosome” used interchangeably with “extracellular vesicle”. 61 
Interestingly, “exosome” has been referenced more often than “extracellular vesicle” 62 
in published manuscripts over the last several decades, reflecting its popularity, yet 63 
this gap has narrowed significantly in 2019, perhaps reflecting research groups new 64 
to the field adopting the correct terminology (Fig. 4). The Minimum Information for 65 
Studies of Extracellular Vesicles (MISEV2018) (Théry and Witwer, 2018) are a 66 
recent published set of guidelines that, in summary, state that the term “EV” should 67 
be used exclusively unless they are confirmed to originate from the exosome 68 
biogenesis pathway (Fig. 2). While we agree with the above guidelines, given that 69 
we are reviewing past and present literature that has yet to take these into 70 
consideration, certain concessions were made. Thus, while many studies refer to 71 
their preparations as “exosomes” as opposed to EV, we will refer to them as EV 72 
unless they fulfill the definition of exosomes detailed recently (Klingeborn et al., 73 
2017a) which are 30-150 nm vesicles loaded with at least some of the exosomal 74 
proteins CD63, CD9, CD81, syntenin-1, and TSG101. We also add a further 75 
requirement to the definition that is often included in most recent studies which is the 76 
use of a 0.22 µm filter, removing contaminating microvesicles (albeit at the cost of a 77 
reduced overall yield) that are often isolated with exosomes in most techniques such 78 
as ultracentrifugation or polyethylene glycol precipitation (Konoshenko et al., 2018; 79 
Ma et al., 2020; Mead and Tomarev, 2017; Pan et al., 2019). Isolation of exosomes 80 
with more intricate techniques such as sucrose gradients, relying on their buoyant 81 
density of about 1.10-1.19 g/ml, are also employed but this is largely restricted to 82 
specialized studies into vesicle mechanics and not therapeutic assessment (Shurtleff 83 
et al., 2016). 84 
A key detail regarding EV and the reason for their great research interest is that their 85 
cargo is expansive, containing proteins, mRNA, miRNA, and lipids. Furthermore, 86 
following secretion from a cell, these vesicles act as mediators of cell signaling, 87 
delivering their cargo into recipient cells and in the case of mRNA/miRNA, lead to the 88 
translation of new proteins/modulation of gene expression, respectively (Ratajczak et 89 
al., 2006; Skog et al., 2008; Valadi et al., 2007). By delivering multiple proteins, 90 
mRNA and miRNA (all of which target multiple different mRNA), EV are intrinsically a 91 
multifactorial treatment. 92 
While the different types of EV are distinct, another variable that defines them is the 93 
source that the EV is secreted from. For example, we recently sequenced miRNA of 94 
exosomes from human BMSC and fibroblasts and identified over 40 candidates that 95 
were distinct between the two samples (Mead et al., 2018b). Several studies have 96 
been published detailing the miRNA within exosomes from multiple MSC types 97 
(Table. 1). While many of the most abundant miRNA are consistent between studies, 98 
it is apparent that some variability even from the same cell type exists, 99 
demonstrating the heterogeneity of MSC cultures as well as the variability between 100 
miRNA library construction/analysis methodologies. Regarding the proteome and 101 
lipidome, distinct differences have been observed between exosomes isolated for 102 
U87 glioblastoma cells, Huh7 hepatocellular carcinoma cells, and BMSC (Haraszti et 103 
al., 2016). Exosomes from distinct retinal cells such as retinal astrocytes 104 
(Hajrasouliha et al., 2013), retinal pigment epithelium (RPE) cells (Klingeborn et al., 105 
2017b), and retinal progenitor cells (Zhou et al., 2018) also contain distinct 106 
proteomes and this is reflected in their therapeutic efficacy (discussed below).  It has 107 
equally been shown that cells secrete exosomes with variable cargo depending on 108 
the stage of differentiation they are in. For example, osteogenic differentiation of 109 
MSC leads to exosome secretion with extracellular matrix mineralization properties, 110 
but only in the late, not early phase of differentiation (Wang et al., 2018b). Even cell 111 
passage has been shown to have an effect on the neuroprotective efficacy of MSC 112 
exosomes, with it diminishing with increasing cell passage of the source (Venugopal 113 
et al., 2017). With the cargo of EV varying depending on their cellular origin, it could 114 
be thus assumed that EV cargo is just a sample of the cellular cytoplasm. However, 115 
proteomic analysis of adipose-derived MSC and EV demonstrated that over 100 116 
proteins were more abundant in EV in comparison to the cell, suggesting that the 117 
loading of EV involves active and specific trafficking (Eirin et al., 2016). Interestingly, 118 
when comparing exosomes to microvesicles, it appears that this specific trafficking 119 
mechanism is more evident in exosomes as their protein population is more distinct 120 
from the host cell’s than the protein population of microvesicles (Haraszti et al., 121 
2016). Comparison of mRNA, miRNA, and transfer RNA abundance between 122 
adipose-derived MSC/T cells and their EV leads to similar conclusions, select mRNA 123 
and miRNA enriched in EV in comparison to the cell (Chiou et al., 2018; Eirin et al., 124 
2014). Likewise, exosomes isolated from HEK293 cells contain selectively packaged 125 
miRNAs compared with HEK293 cells and it was found that the RNA-binding Y-box 126 
protein (YBX1) binds to and is required for the sorting of certain miRNAs (mir-223) in 127 
exosomes (Shurtleff et al., 2016).  128 
Along with their cargo, the number of exosomes released by cells can also vary 129 
greatly. In a comparison of several cell types including myoblasts and HEK cells, 130 
MSC secreted a significantly greater number (>10-fold) of exosomes (Yeo et al., 131 
2013). Finally, along with the differences between the three types of EV, within each 132 
type they may be further divided into subtypes. Exosomal surface proteins can be 133 
analyzed using flow cytometry and antibody-bead conjugates which, although cannot 134 
quantify exosomes due to an inability in knowing how many exosomes have bound 135 
to each bead, does demonstrate considerable differences between sub populations 136 
that possess or lack exosomal proteins such as CD63 (Mead and Tomarev, 2017). 137 
To analyse these subtypes, more homogeneous population of exosomes are 138 
obtained through the inclusion of additional purification steps such as a flotation of 139 
exosomes to an interface between 20 and 40% sucrose and immunoprecipitation 140 
with CD63 antibody-immobilized beads (Shurtleff et al., 2016) or high-resolution 141 
iodixanol density gradient fractionation (Jeppesen et al., 2019). A distinct difference 142 
in the RNA cargo between the “high density” and “low density” exosomes (Jeppesen 143 
et al., 2019; Shurtleff et al., 2016) and distinct functional differences between them 144 
(Willms et al., 2016) has been reported, yet it remains to be seen if these distinctions 145 
are relevant when it comes to developing potential therapies for the eye. These 146 
additional purification and subtype separation techniques are not typically employed 147 
in research outside exosome-focused research groups and thus their therapeutic 148 
and biological relevance is largely unexplored. 149 
One considerable benefit EV offer over cellular therapy as a treatment is their 150 
storage properties (Kusuma et al., 2018). EV RNA quality showed little to no 151 
deterioration after storage for 5 years at -20°C in comparison to fresh EV while 152 
storage at 4°C for 2 weeks led to significant degradation in some RNA (Ge et al., 153 
2014). This can be partly explained by their bi-lipid membranes, which protects the 154 
cargo from enzymatic/chemical degradation. Another benefit is the safety in 155 
comparison to injections of dividing/differentiating cells into the eye. A recent report 156 
detailed three patients who received intravitreal injections of adipose-derived MSC 157 
as a treatment for age-related macular degeneration (AMD). Unfortunately, these 158 
patients subsequently went blind due to a variety of complications associated with 159 
the stem cell transplant including retinal detachment and hemorrhage (Kuriyan et al., 160 
2017). The formation of a monolayer of cells on the inner limiting membrane of the 161 
retina  is heavily involved in the pathology of retinal detachment and proliferative 162 
vitreoretinopathy (Yang et al., 2015) and these cells originate from the epithelial-163 
mesenchymal transition of RPE cells. Given that transplanted MSC adhere and 164 
cluster to the inner limiting membrane (Mead et al., 2016), it is possible that these 165 
transplanted cells formed epiretinal membranes as observed in one patient receiving 166 
MSC (Kim et al., 2017). A more recent study transplanting MSC into the vitreous of 167 
rats also demonstrated significant vascular damage alongside glial activation and an 168 
inflammatory response (Huang et al., 2019). Cell therapy is also compounded by an 169 
unknown division rate and rate of death after transplantation, meaning a known 170 
number of cells quickly becomes unknown after administration. While the above 171 
does not mean cellular therapy is unfeasible, these complications are avoided by 172 
purifying the active secreted compound, believed to be EV (as well as neurotrophic 173 
proteins), and administering this in the place of the cells. It can be argued that EV 174 
therapy is more controlled regarding its dose since there is no risk of division 175 
occurring post-transplantation. However, both cells and EV share a dosing problem 176 
that is intrinsic to their role as deliverers of a multifactorial cargo. Given that this 177 
cargo varies between passages (Mead et al., 2014) and donors (Table. 1), using the 178 
same number of cells/EV does not guarantee that the therapeutic cargo is being 179 
correctly dosed. Finally, a large disadvantage with retinal cell therapy is the lack of 180 
integration of transplanted cells into the retina (Emre et al., 2015; Johnson et al., 181 
2010a; Mead et al., 2013) unless further measures are taken such as digestion of 182 
the inner limiting membrane and modulation of retinal glial activity (Johnson et al., 183 
2010b), which may itself damage the retina. EV therapy avoids this complication and 184 
can pass through the inner limiting membrane with ease (Mead and Tomarev, 2017). 185 
3. Retinal Disease 186 
EV are a strong candidate as a cell free therapy and below we discuss current 187 
evidence for their use in various diseases affecting the retina. 188 
3.1. Optic Nerve Crush 189 
Optic nerve crush is a model of traumatic optic neuropathy, a severe acute condition 190 
in which the delicate optic nerve, on its path from the retina to the lateral geniculate 191 
nucleus/superior colliculus, is physically injured. Crushing of the optic nerve in mice 192 
and rats leads to a 50% loss of RGC by 7 days and 90% loss by 14 days (Berkelaar 193 
et al., 1994; Leung et al., 2008; Rodriguez et al., 2014). Not only is it characterized 194 
by the selective loss of RGC but also the Wallerian degeneration of RGC axons that 195 
fail to regenerate (Berry et al., 2008). Finally, the optic nerve crush model appears to 196 
selectively kill certain RGC subtypes while largely preserving others, and in 197 
particular, α-RGC and melanopsin-expressing M1-RGC demonstrating robust 198 
survival in comparison to other RGC subtypes (Duan et al., 2015; Tran et al., 2019). 199 
Recently we transplanted exosomes derived from BMSC into the vitreous of rats 200 
after optic nerve crush (Mead and Tomarev, 2017). Exosomes delivered their cargo 201 
into RGC, as shown by preloading the exosomes with a fluorescent marker, and 202 
provided significant neuroprotection and functional preservation, whereas long-203 
distance axon regeneration was not observed. Fibroblast exosomes, which were 204 
used as control exosomes, provided no therapeutic effects. BMSC exosomes also 205 
preserved RGC function by over 50%, as measured by electroretinography. Since 206 
preventing RGC death does not inherently mean a prevention of RGC dysfunction 207 
(Fry et al., 2018), this result suggests exosomes work through multiple pathways to 208 
not only protect RGC but also distinctly preserve their function. Interestingly, 209 
exosomes appeared to be the therapeutically efficacious EV whereas microvesicles 210 
were not and were even toxic to RGC at higher concentrations (Mead and Tomarev, 211 
2017) (Fig. 5b), an observation seen also in a retinal ischemic model (discussed 212 
below, van der Merwe et al., 2019) as well as in cortical neuron cultures (Lopez-213 
Verrilli et al., 2016). The mechanism of action was determined to be, at least 214 
partially, due to the miRNA evident by the ablation of therapeutic efficacy if AGO2 is 215 
knocked down in BMSC. AGO2 is a protein that forms part of the miRNA complex 216 
and is necessary for their ability to inhibit mRNA translation. Knocking down AGO2 in 217 
cells prior to EV isolation leads to EV lacking in mature miRNA (Lv et al., 2014; 218 
Zhang et al., 2016). We can speculate that differences between the cargo packaged 219 
in exosomes and microvesicles (e.g. proteins and/or RNA) is the reason for their 220 
opposing effects on neurons but further investigations into the mechanism of action 221 
are needed before this can be corroborated. 222 
Further studies by Pan and coauthors transplanted exosomes derived from umbilical 223 
cord MSC into the vitreous of rats after optic nerve crush (Pan et al., 2019). As we 224 
had previously defined, by removing microvesicles through the use of a 0.22µm filter, 225 
significant RGC neuroprotection was achieved and similarly, RGC axon regeneration 226 
was not. Authors also demonstrated significant glial activation. Interestingly the effect 227 
was not as significant as seen with BMSC exosomes and authors reasoned that this 228 
is due to the reported differences in exosomal miRNA between those isolated from 229 
BMSC (Baglio et al., 2015; Mead et al., 2018b) and UMSC (Fang et al., 2016). 230 
A separate study utilized exosomes isolated from L-cells, a fibroblast cell line 231 
(Tassew et al., 2017). It is worth noting that in this study, authors did not filter their 232 
EV or fully define their preparation. Thus, their preparation is more accurately 233 
referred to as EV, a mixture of exosomes and microvesicles. Authors did not observe 234 
any significant neuroprotection of RGC but interestingly, observed significant 235 
regeneration of RGC axons. The mechanism of action appears to be due to the 236 
recruitment of Wnt10b to lipid rafts and subsequent activation of the axogenic mTOR 237 
pathway via GSK3β. This distinction between L cell exosomes/EV and MSC 238 
exosomes in the axogenic effect is likely due to a difference in their internal cargo. 239 
We recently sequenced L cell exosome miRNA and performed a comparison 240 
between them and BMSC/fibroblast exosomes. (Fig. 6). Their miRNA profile is 241 
shown with the majority distinct from that found in BMSC exosomes, although some 242 
similarities were observed (Figure. 6b). The difference in RGC neuroprotection 243 
observed could also be explained by the exosome isolation technique. Microvesicles 244 
were included in the authors preparation (i.e. not filtered out), and our observation of 245 
their toxicity on RGC (Mead and Tomarev, 2017) suggests L cell exosomes may 246 
indeed be neuroprotective but is obfuscated by microvesicle-induced RGC death. 247 
In the above studies, BMSC (Mead and Tomarev, 2017) and umbilical cord MSC 248 
(Pan et al., 2019) exosomes both promoted neuroprotection without axon 249 
regeneration whereas L-cell exosomes (Tassew et al., 2017) did the opposite. This 250 
confirms the distinction between the pathways involved in neuroprotection and those 251 
for axon regeneration. It has been shown that Sox11 expression promotes axonal 252 
regeneration for some RGC subtypes yet for some subtypes promotes their death 253 
(Norsworthy et al., 2017). It is possible that despite the expansive cargo of MSC 254 
exosomes, they do not properly activate regeneration pathways which also include 255 
pten/socs3 modulation (Sun et al., 2011) and induction of neural activity (Lim et al., 256 
2016). This may represent a benefit of cell therapy over EV as MSC have been 257 
demonstrated to reliably stimulate both regeneration and survival (Mesentier-Louro 258 
et al., 2019; Mesentier-Louro et al., 2014; Tan et al., 2015). 259 
3.2. Glaucoma 260 
Glaucoma bares some similarities to optic nerve crush in that it is also characterized 261 
by the selective death of RGC (Almasieh et al., 2012). In contrast, the death is a 262 
slow, progressive degeneration as opposed to acute loss and thus, is a more sinister 263 
condition. The principle risk factor is an elevation in intraocular pressure (IOP) which 264 
is believed to cause compression of the optic nerve at the lamina cribrosa. IOP is 265 
only a risk factor not a cause however, owing to the fact glaucoma can occur with 266 
normal IOP values (Coleman and Miglior, 2008). The mechanism by which RGC die 267 
in glaucoma is still not fully understood and studies demonstrate a myriad of 268 
processes responsible including NTF deprivation, excitotoxicity, inflammation, 269 
oxidative stress, and antero/retrograde axon transport dysfunction (Reviewed in 270 
Almasieh et al., 2012; Syc-Mazurek and Libby, 2019). For a treatment to be effective 271 
in preventing RGC death and dysfunction it must be equally multifactorial to address 272 
these injury processes. Previous success has been found through transplantation of 273 
MSC (Fig. 1) which secrete of a multitude of beneficial factors (Emre et al., 2015; 274 
Harrell et al., 2019; Johnson et al., 2010a; Mead et al., 2013; Mesentier-Louro et al., 275 
2019; Mesentier-Louro et al., 2014). 276 
We recently transplanted BMSC exosomes into the vitreous of three separate animal 277 
models of glaucoma: laser and microbead rat models (Mead et al., 2018b), and a 278 
genetic DBA/2J mouse model (Mead et al., 2018a). In all three models, BMSC 279 
exosomes promoted significant survival of RGC along with preventing their functional 280 
decline that is characteristic of glaucoma models. In the DBA/2J model, we also 281 
observed a protective effect on RGC axons. As with the optic nerve crush model, we 282 
used fibroblast exosomes as a negative control as they elicited no therapeutic effect 283 
in these three models of glaucoma. One interesting finding was that the efficacy of 284 
exosomes was maintained even when delivered on a monthly basis but failed to elicit 285 
neuroprotection if the treatment was delivered more infrequently. The DBA/2J mice 286 
are a 12-month model of glaucoma and exosomes were still efficacious over this 287 
time period. 288 
The mechanism of action appeared to be, as before, due to the miRNA cargo they 289 
delivered into RGC. This was confirmed through AGO2 knockdown and the ablation 290 
of neuroprotection (Mead et al., 2018b). To determine which miRNA were 291 
responsible for these therapeutic effects, miRNAseq was performed, comparing 292 
miRNA in the efficacious MSC exosomes to the ineffective fibroblast exosomes. 293 
Previous studies have already profiled MSC EV/exosomes and mapped out the most 294 
abundant miRNA (Ferguson et al., 2018; Qian et al., 2016; Sun et al., 2017) (Table 295 
1) and we identified 43 miRNA that were abundant in BMSC exosomes in 296 
comparison to fibroblast exosomes (Mead et al., 2018b). Given that miRNA target a 297 
great many different mRNA, it is difficult to determine which molecules and pathways 298 
are responsible for the therapeutic effects observed. Many of these targets are still 299 
only predictions with only a fraction tested and experimentally observed. Within 300 
these targets however, well known instigators of RGC death including the bcl2 family 301 
(Maes et al., 2017), tnf (Tezel, 2008), and pten/mtor (Morgan-Warren et al., 2016) 302 
exist and further study will determine to what extent exosome-derived miRNA is 303 
acting through these pathways. 304 
This data suggests that exosomes may serve as a suitable neuroprotective strategy, 305 
both in glaucoma that is not amenable to IOP lowering therapies, or as an adjunctive 306 
treatment. Another important conclusion is that long-term exosome treatment could 307 
be developed that requires only a monthly injection, as is done with anti-vascular 308 
endothelial growth factor (VEGF) treatments for AMD. This is likely based on a 309 
combination of the stability of exosomes as well as miRNA whose stability is 310 
reported to be over several days (Bartel, 2018). 311 
In an effort to determine if the therapeutic effects we and others have observed is 312 
also applicable to human retina, we tested exosomes in a human in vitro retinal 313 
culture (Sluch et al., 2017; Sluch et al., 2015). Human embryonic stem cell lines 314 
were differentiated into retinal cells, which included RGC, and were injured using the 315 
microtubule poison colchicine (Mead et al., 2020). Delivery of BMSC-derived 316 
exosomes provided significant neuroprotection of human RGC (Fig. 7). While we 317 
would certainly not argue that this in vitro system models glaucoma, it does provide 318 
evidence that the efficacy we are seeing in animal models may indeed be 319 
translatable to the human condition. More studies are needed using human tissue to 320 
strengthen this argument.  321 
3.3. Retinal Ischemia 322 
Retinal ischemia, such as due to occlusion of the retinal artery or detachment of the 323 
retina, causes significant and irreversible damage. As with glaucoma, transplantation 324 
of MSC has shown efficacy at preventing retinal cell loss and dysfunction (Dreixler et 325 
al., 2014) and also, as with glaucoma, exosomes isolated from BMSC were able to 326 
recapitulate the effects of BMSC when transplanted into the vitreous of retinal 327 
ischemic mice, induced by hyperoxic conditioning (Moisseiev et al., 2017). These 328 
therapeutic effects included a significant reduction in retinal thinning and 329 
neovascularization and were present 14 days after the treatment. The ability of 330 
exosomes to prevent neovascularization is also seen in the choroid following delivery 331 
of retinal astrocyte-derived exosomes but is not seen when using RPE-derived 332 
exosomes (Hajrasouliha et al., 2013), again demonstrating the importance of the 333 
exosome source. 334 
A more recent study utilized a brief elevation in IOP (15 to 150mmHg for 60 minutes) 335 
to induce retinal ischemia in rats (van der Merwe et al., 2019). EV were isolated from 336 
bioscaffolds and in particular, decellularized porcine urinary bladder matrix. These 337 
EV, known as matrix bound nanovesicles are similar to exosomes in that they are 338 
lipid membrane bound, containing protein and RNA, although their exact cargo 339 
profile may differ. The characterization of these matrix bound nanovesicles, including 340 
size or RNA/protein abundance was however not shown and thus it is unknown if 341 
these matrix bound nanovesicles are indeed just EV that have become associated 342 
with the scaffold following secretion. Evidence for this is shown when RGC in 343 
cultures are treated with membrane bound nanovesicles, which promoted 344 
neuritogenesis with increasing dosage, but a bi-phasic effect was observed with the 345 
neuritogenic effect dissipating at very high doses (Fig. 5c). This observation mirrored 346 
what we observed whereby MSC EV promoted neuritogenesis of RGC in a bi-phasic 347 
dose responsive manner (Mead and Tomarev, 2017). We had confirmed that this 348 
negative effect at increasing doses was due to microvesicles, and their removal from 349 
the EV sample, leaving just exosomes, ablated the bi-phasic dose response effect 350 
(Fig. 5b). Lopez-Verrilli and coauthors (Fig. 5a) also demonstrated a similar effect 351 
on cortical neurons with exosomes eliciting neuritogenesis while microvesicles did 352 
not (Lopez-Verrilli et al., 2016). Thus, it is possible microvesicles were present in the 353 
authors preparation. Despite this, authors demonstrated that EV treatment prevented 354 
microglia/astrocyte activation-induced release of the pro-inflammatory cytokines 355 
interleukin (IL)-1β, IL-6, and TNF-α, significantly reducing subsequent RGC 356 
degeneration in vitro and in vivo (van der Merwe et al., 2019). Finally, authors also 357 
demonstrated that the intravitreal delivery of these EV reduced loss of cholera toxin 358 
b-subunit+ RGC axons as well as dysfunction in RGC, as measured by the photopic 359 
negative response. 360 
Retinal ischemia can also occur when the retina becomes detached from the 361 
choroid, from which is depends on for its blood supply. In a rat model of retinal 362 
detachment, injection of BMSC-derived exosomes reduced the expression of pro 363 
inflammatory cytokines such as TNF-α while upregulating autophagy (Ma et al., 364 
2020). Authors demonstrated a subsequent neuroprotective effect on 365 
photoreceptors, reducing cell loss despite the detached retina. While a mechanism 366 
of action was not deduced, authors did note the abundance of exosomal proteins 367 
with neuroprotective and anti-inflammatory properties. 368 
3.4. Retinal Laser Injury 369 
A separate model of retinal injury utilizes a laser, not to burn the outflow pathways 370 
like in glaucoma but to directly burn the retina. Several laser burn spots are delivered 371 
to the retina, which initiates indiscriminate rather than specific cellular degeneration 372 
alongside inflammation. 373 
Delivery of MSC EV (unfiltered exosomes) into cultures of retinal cells after heat 374 
induced injury, or into the vitreous of mice after laser injury provided significant 375 
neuroprotection of retinal cells to the same efficacy as the MSC themselves (Yu et 376 
al., 2016). Along with a reduction in TUNEL+ retinal cells/thinning of retinal layers, 377 
MSC EV also prevented declines in A- and B-wave amplitudes, suggesting a 378 
preservation of photoreceptor and bipolar cell function, respectively. MSC EV 379 
diffused throughout the retina and RPE within one hour. One mechanism identified 380 
by the authors was the exosome-induced down-regulation of MCP-1 retinal 381 
expression, whose upregulation is usually a consequence of retinal injury. MCP-1 is 382 
a chemotactic cytokine that attracts macrophages and microglial cells into the injury 383 
site, leading to further damage and degeneration. MSC EV reduced MCP-1 384 
expression in vitro and in vivo, reducing macrophage infiltration and this effect was 385 
abolished if MCP-1 was delivered into animals. This study reveals another 386 
mechanism of action for EV, an anti-inflammatory one, yet did not determine if the 387 
down-regulation of MCP-1 was due to the EV protein or RNA cargo. 388 
A separate study focused on the effects of laser damage to RPE, which causes 389 
choroidal neovascularization, a characteristic feature of wet AMD (He et al., 2018). In 390 
vitro, laser damage to RPE cells induced the production of VEGF, the principal 391 
growth factor responsible for the neo-vascularization and the basis for the anti-VEGF 392 
drugs used in the clinic. Treatment of laser-injured RPE cells with umbilical cord 393 
MSC-derived EV reduced the transcription and translation of VEGF whereas in vivo, 394 
delivery of EV did the same while reducing retinal damage as measured by fundus 395 
fluorescein angiography.  396 
In the same in vivo model of choroidal neovascularization, Hajrasouliha and 397 
coauthors demonstrated that exosomes from retinal astrocytes can inhibit the 398 
formation of new blood vessels as well as suppress retinal vascular leakage 399 
(Hajrasouliha et al., 2013). Similar to other studies, a 0.22µm filter was employed to 400 
filter out microvesicles. The authors state that the mechanism of action is likely 401 
through the inhibition of macrophage migration which is a major source of 402 
inflammatory cytokines as well as VEGF. Interestingly, authors attributed the 403 
therapeutic effects to the protein content of exosomes and identified several anti-404 
angiogenic candidates abundantly found in retinal astrocyte-derived exosomes. By 405 
inhibiting the MMP-induced production of endostatin and utilizing the subsequently 406 
generated endostatin-free exosomes, suppression of vascular leakage was no 407 
longer observed, demonstrating a role for exosome-delivered endostatin. 408 
3.5. Autoimmune Uveitis 409 
Uveitis is an inflammatory condition of the eye requiring immunosuppressive 410 
treatment. Since long-term use of immunosuppression comes with several side 411 
effects, there is still a need for new treatments. Interphotoreceptor retinol-binding 412 
protein immunization induces experimental autoimmune uveitis, and the 413 
inflammatory cell retinal infiltration (granulocytes, natural killer cells, macrophages, 414 
and T cells) is ameliorated after treatment with umbilical cord MSC exosomes 415 
(filtered and characterized) (Bai et al., 2017). MSC exosomes also prevented a loss 416 
in A- and B-wave amplitude, suggesting photoreceptor and bipolar cell function was 417 
preserved. Authors found that the MSC exosomes anti-inflammatory effects were 418 
specifically on T cell migration and not proliferation/apoptosis. While the study did 419 
not determine their mechanism of action, previous studies have shown that MSC 420 
exosomes inhibit macrophage activation through miRNA-mediated down-regulation 421 
of the toll-like receptor and nuclear factor kappa B (NF-kB) pathway (Phinney et al., 422 
2015). Other mechanisms such as the polarization of CD4+ T cells to regulatory T 423 
cells has also been described (Bin et al., 2014). 424 
A separate study testing the effects of MSC exosomes in experimental autoimmune 425 
uveitis delivered exosomes into the tail vein (Shigemoto-Kuroda et al., 2017). 426 
Exosomes were isolated by column fractionation and characterized using exosomal 427 
markers CD63 and CD81. MSC exosomes performed just as well as MSC in 428 
preventing photoreceptor layer disruption and inflammatory cell infiltration. 429 
Interestingly, only a single injection was administered at the beginning of the 21 day 430 
study, corroborating our own reports of MSC exosomes remaining efficacious for up 431 
to 1 month in the eye (Mead et al., 2018a; Mead et al., 2018b). MSC exosomes/MSC 432 
also reduced the transcription of many pro-inflammatory cytokines including 433 
interferon gamma (IFN-g), IL-17A, IL-2, IL-1b, IL-6, and IL-12A (Shigemoto-Kuroda 434 
et al., 2017). Unlike the previous study however, authors demonstrated that MSC 435 
exosomes suppressed T cell proliferation. One possible explanation for this 436 
discrepancy is that authors cultured their MSC in serum free medium designed to 437 
activate/prime the MSC prior to exosomes isolation, which would likely have 438 
changed their internal cargo and thus, therapeutic action. 439 
The anti-inflammatory properties of EV have also been demonstrated by RPE, 440 
whose secreted EV provide immunomodulatory effects on monocytes and even 441 
induce their death (Knickelbein et al., 2016). Currently however, they have not been 442 
utilized as a potential therapeutic. 443 
These studies suggest that MSC EV and in particular exosomes have potential as a 444 
treatment in inflammatory diseases of the eye. Further studies on their long-term 445 
efficacy, dose and ideal source of said exosomes are needed to improve the 446 
treatment. One exciting observation is MSC EV efficacy is still present when 447 
delivered into the blood stream rather than the eye, suggesting that they can home 448 
into an injured environment (Shigemoto-Kuroda et al., 2017). While this would be a 449 
more ideal route of administration from the patient’s perspective, the potential for off-450 
target effects with pernicious consequences would need to be considered. The anti-451 
inflammatory properties of EV are not just relevant to uveitis but also the retinal injury 452 
models discussed above. Retinal/optic nerve injury is followed by a polarization of 453 
microglia to a M1 pro-inflammatory phenotype, which secrete various inflammatory 454 
cytokines including TNF-α. These can not only directly induce the neurodegeneration 455 
of RGC (Tezel, 2008) but polarize astrocytes to a neurotoxic A1 phenotype which 456 
itself leads to RGC neurodegeneration (Liddelow et al., 2017). Further studies are 457 
required to determine if these anti-inflammatory effects are a relevant mechanism 458 
behind the EV-mediated neuroprotection previously discussed. 459 
3.6. Diabetic Retinopathy 460 
Diabetic retinopathy, a consequence of diabetes mellitus that involves inflammation, 461 
microaneurysms, vasculature damage and subsequent neo-vascularization (Stitt et 462 
al., 2016) has also shown preliminary promise as an eye disease amenable to EV 463 
therapy. Delivery of MSC (adipose-derived) EV into the eye, either subconjunctival or 464 
intravitreous (but not intravenous) prevented significant retinal degeneration (Safwat 465 
et al., 2018) in a streptozotocin-induced model of diabetic retinopathy. Authors 466 
demonstrated that exosomes delivered miRNA-222 into the retina and restored 467 
falling levels typically associated with diabetic retinopathy. The discrepancy between 468 
this study’s inability to obtain a clinical effect after intravenous administration, and 469 
the positive effects seen in the above study (Shigemoto-Kuroda et al., 2017) 470 
emphasize the need for further investigation on this potential route of administration. 471 
A separate study utilized the same model and delivered umbilical cord MSC 472 
exosomes intravitreally (Zhang et al., 2019). Hyperglycemia-induced inflammation is 473 
ameliorated by MSC exosomes in comparison to fibroblast exosomes, as measured 474 
by ELISA for the inflammatory markers IL-1β, IL-18, and caspase-1 in the vitreous. 475 
The mechanism of action appears to be miR-126-mediated inhibition of the high 476 
mobility group box 1 (HMGB1) signaling pathway. Diabetic retinopathy is associated 477 
with decreased miR-126 and over expression of miR-126 in MSC exosomes further 478 
augmented the therapeutic efficacy. 479 
3.7. Clinical Trials 480 
As of this review 148 clinical trials have been listed looking at “exosomes” and 39 481 
mentioning “extracellular vesicles”. However, very few are utilizing them as a therapy 482 
with the rest mostly focusing on the use of exosomes as biomarkers of disease. 483 
Two of these clinical trials testing MSC EV therapies that have been published 484 
include in steroid refractory graft-versus-host disease (Kordelas et al., 2014) and in 485 
chronic kidney disease (Nassar et al., 2016). MSC EV reduced pro-inflammatory 486 
cytokine secretions including TNF-α, increased anti-inflammatory cytokines 487 
secretions including TGF-β, and improved patient recovery and kidney function. 488 
Two clinical trials are listed using exosomes as a treatment for eye disease, one in 489 
diabetic retinopathy which is not yet recruiting (ClinicalTrials.gov Identifier: 490 
NCT03264976) and another for the treatment of macular holes which is still 491 
recruiting and has already published preliminary results (ClinicalTrials.gov Identifier: 492 
NCT03437759). Five patients with large and refractory macular holes were treated 493 
with an intravitreal delivery of MSC-derived exosomes (Zhang et al., 2018). 494 
Exosomal presence was confirmed using western blot, staining for exosome markers 495 
such as CD63, CD9 and CD81. Since no size exclusion (e.g. 0.22µm filter) was 496 
utilized, the preparation undoubtedly also included microvesicles and is thus more 497 
accurately described as MSC EV. Results of the study suggest that MSC EV 498 
stimulate the closure of macular holes although the mechanism of action was not 499 
elucidated, and control groups not included. The intravitreal MSC EV therapy was 500 
well tolerated with only one patient experiencing an inflammatory reaction which was 501 
not present when the dose was reduced. 502 
As more studies demonstrate that EV have an active and potentially therapeutic role 503 
in the body, as opposed to only a passive one (Joo et al., 2020; Tieu et al., 2019), it 504 
is anticipated that there will be more clinical trials focusing on their clinical potential 505 
rather than their role solely as biomarkers. 506 
4. Future Considerations 507 
While EV show great promise, many questions still remain unanswered. 508 
4.1. Toxicology and Dosing 509 
While no evidence exists for any complications arising from delivery of EV into the 510 
eye, extensive toxicology studies are still needed. Some in vitro (Maji et al., 2017) 511 
and in vivo (Zhu et al., 2017) toxicology reports have been published detailing their 512 
safety after culture treatment or systemic delivery, but how true this is for ocular 513 
delivery is still not known. They also report toxicological differences between 514 
different cellular sources of EV which although is unsurprising given what we know, 515 
emphasizes the importance of treating EV from different cells as distinct agents. 516 
Secondly, the large-scale production of clinical-grade EV represents a significant 517 
barrier to moving this experimental treatment into the clinic. Issues such as ensuring 518 
the batch-to-batch variability remains minimal as well as the detection of any viruses 519 
that will likely be enriched alongside EV remains paramount when moving forward 520 
(Rohde et al., 2019). Variations in the length of time in culture may also affect the 521 
cells and subsequently, the EV, increasing variability. For EV to be effectively dosed, 522 
it is not enough to simply consider their quantity but instead to dose for their cargo, 523 
ensuring that a controlled amount of the therapeutically efficacious elements are 524 
delivered irrespective of the number of EV particles.  It is also important to consider 525 
that the therapeutically efficacious component of the isolate may indeed be an EV 526 
subtype that can be further purified, however techniques to achieve this are still 527 
lacking (Greening and Simpson, 2018) and the benefits would need to be balanced 528 
against the added cost. Along with the EV subtype, the subtypes of the target cells 529 
should also be taken into consideration. Using RGC as an example, just as different 530 
injuries affect different RGC subtype, it is also possible that EV treatment only 531 
protects specific RGC subtypes and given that over 40 subtypes have been 532 
identified (Reviewed in Sanes and Masland, 2015; Tran et al., 2019), these potential 533 
differential effects warrant investigation. Regarding large scale EV production, one 534 
research focus has been to target the MSC themselves, modifying them in such a 535 
way as to improve the isolated EV yield and efficacy (Phan et al., 2018).  536 
4.2. Targeting EV to Cells 537 
For EV to exert their effects on the injured retina, they must be targeted to the 538 
correct cells and subsequently internalized. The above studies have demonstrated 539 
that EV deliver cargo into a whole range of retinal cells including RGC (Mead and 540 
Tomarev, 2017), microglia, astrocytes (van der Merwe et al., 2019), and RPE cells 541 
(He et al., 2018). However, many studies do not interrogate the exact cellular target, 542 
only referencing global changes in retinal expression, function, or morphology. 543 
Future studies should pay special attention to this aspect of EV, particularly as it is 544 
becoming apparent EV can preferentially bind to specific cells based on their protein 545 
cargo (Murphy et al., 2019). Thus, particular EV can be selected depending on the 546 
desired retinal cell target.  547 
4.3. Mechanisms of Action and the Discovery of Novel Pathways 548 
It is clear that EV contain an expansive cargo while unclear which of this cargo is 549 
responsible for the therapeutic effects observed in the above retinal diseases. It is 550 
tempting, and perhaps more feasible, to focus on clearly established pathways and 551 
delineate from this which of the EV cargo is likely responsible. However, EV also 552 
represent an opportunity to discover novel targets, particularly given most miRNA 553 
targets are untested and remain predicted rather than observed (Mead et al., 2018b). 554 
Research has often used EV in a cross-species manner, in particular, human-555 
derived EV in rodent models. It is unclear what interactions and effects are being 556 
excluded due to, for example, particular human-miRNA being incompatible with 557 
rodent mRNA. More studies using human EV on human cells may help refine the 558 
mechanisms or yield new candidates. If the mechanism of action can be limited to 559 
just a select few miRNA/mRNA/proteins, the treatment could be further simplified just 560 
using these particular candidates. Finally, it is currently unknown what the miRNA 561 
landscape of RGC (and their subtypes) is, as well as other specific retinal cells. This 562 
is important information considering the delivery of miRNA is one important 563 
mechanism of EV. It would be equally important to know the retinal mRNA/miRNA 564 
changes before and after EV treatment as well as under different injury conditions. 565 
Additionally, knowing the EV signaling that occurs to maintain eye homeostasis will 566 
help shape future EV therapies. 567 
4.4. EV Modification, Priming, and Loading 568 
While it is clear EV are therapeutically efficacious in several disease models, how 569 
this effect can be improved further is of strong interest and may allow lower doses or 570 
less frequent administrations to be utilized. Modifying EV to better target cells of 571 
interest is one such approach and is demonstrated in a previous study involving the 572 
fusion of the exosomal protein lysosome-associated membrane protein 2 (Lamp2b) 573 
with the brain targeting peptide rabies viral glycoprotein peptide (Alvarez-Erviti et al., 574 
2011). Subsequently generated EV were able to selectively target neurons, 575 
microglia, and oligodendrocytes in the brain after systemic administration. Priming or 576 
modifying the EV is another approach and we have recently demonstrated that by 577 
exposing MSC to the inflammatory cytokine TNF-α, the EV they release are more 578 
efficacious in the context of retinal neuroprotection (Mead et al., 2020) (Fig. 7). 579 
These “primed” EV warrant further investigation as it is expected that a cocktail of 580 
factors is required to maximally prime MSC and their EV. EV themselves can be also 581 
be modified directly, such as loaded with an abundance of a particular miRNA to 582 
increase their efficacy. This was achieved in a study described above, loading EV 583 
with miR-126 and increasing their efficacy further in a model of diabetic retinopathy 584 
(Zhang et al., 2019).  585 
5. Conclusions 586 
Exosomes/EV are strong candidates as a treatment for the injured retina. They 587 
circumnavigate the risk factors associated with delivering dividing cells into the eye 588 
while still possessing their multifactorial mechanism of action due to their expansive 589 
cargo. Further work is needed to characterize their mechanism of action including 590 
the mRNA, miRNA and proteins responsible alongside the myriad of therapeutic 591 
targets. 592 
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 972 
Fig. 1. Retinal ganglion cell (RGC) counts in a rat model of glaucoma after 973 
mesenchymal stem cell (MSC) treatment. Glaucoma was modeled through 974 
intracameral injections of TGF-β for 35d. Treatments consisted of intravitreal 975 
transplantation of dental pulp stem cells (DPSC), bone marrow MSC (BMSC), 976 
adipose-derived stem cells (ADSC) and dead DPSC (sham-treated; A). Retinae were 977 
stained with the phenotypic RGC marker BRN3A (red) and the nuclear marker DAPI 978 
(blue; scale bar: 50µm). In (B), GFP+ MSC stained for the MSC marker STRO1 are 979 
identified in the vitreous, adhering to the inner limiting membrane. In (C), the mean 980 
number of BRN3A+ RGC in a 1mm region of retina either side of the optic nerve 981 
head is shown from each of the above groups. Note the significant neuroprotective 982 
effect elicited by the transplanted MSC. Black lines indicate significant difference 983 
between groups (p<0.01). Modified Fig.4 from Mead et al., 2016, re-used under the 984 
Creative Commons Attribution 4.0 International (CCBY4.0) licence. 985 
Fig. 2. Schematic diagram detailing exosomal treatment of the retina. Exosomes and 986 
microvesicles are isolated through ultracentrifugation of culture medium, conditioned 987 
by the proposed cell source. Lower speeds of centrifugation can be used in protocols 988 
that utilize polyethylene glycol while other techniques such as passing through a 989 
sucrose gradient are employed to further specify the vesicle size obtained. To purify 990 
the 30-150nm exosomes from the 100-1000nm microvesicles, passage through a 991 
0.22µm filter is utilized. Following purification, exosome identity can be confirmed 992 
with Nanoparticle Tracking Analysis and Western blot before injection into the eye 993 
(vitreous or subretinal). 994 
Fig. 3. Electron microscopy images of exosomes before and after filtration through a 995 
0.22µm filter along with corresponding Nanosight/Nanoparticle Tracking Analysis of 996 
quantity and size.  Modified Fig.2 from Mead et al., 2018 and Mead et al., 2017, re-997 
used under the Creative Commons Attribution 4.0 International (CCBY4.0) licence. 998 
The figure inset shows a higher quality electron microscopy image of an exosome 999 
(EXO), microvesicle (MV), and apoptotic body (APO). Reused from Osteikoetxea et 1000 
al., 2015 with permission under the Creative Commons Attribution 4.0 International 1001 
(CCBY4.0) licence. 1002 
Fig. 4. Publications with the keyword “exosome” or “extracellular vesicle” in the 1003 
abstract/title from Jan 1st 1980 – Jan 1st 2020. Note the exponential rise in 1004 
publications referencing exosomes along with the historical popularity of “exosome” 1005 
over “extracellular vesicle”, with the gap narrowing significantly in 2019. 1006 
Fig. 5. Differential effects of exosomes and microvesicles on retinal ganglion cells 1007 
(RGC)/neurons. In three separate studies, one in cortical neurons (A) and 2 in RGC 1008 
(B/C), exosomes demonstrated a neuritogenic/neuroprotective effect with 1009 
microvesicles exerting the opposite. The first study (A) showed that exosomes were 1010 
neuritogenic whereas the effect of microvesicles was worse than untreated controls. 1011 
The second (B) demonstrated the efficacy of extracellular vesicles diminished at 1012 
higher doses and this was due to the contamination of microvesicles. A third study 1013 
(C) showed the same but did not confirm the effect was due to contaminating 1014 
microvesicles.  Modified Fig.3 from Loppez-Verrilli et al., 2016 (A), Fig.3 from Mead 1015 
et al., 2017 (B), and Fig.1 from van der Merwe et al., 2019, re-used under the 1016 
Creative Commons Attribution 4.0 International (CCBY4.0) licence. 1017 
Fig. 6. miRNA in L cell exosomes. miRNAseq was performed on exosomes derived 1018 
from L cells with those detected displayed (A) as mean estimated abundance 1019 
(derived from the reads) ± standard error mean (SEM). Mouse L cell exosome 1020 
miRNA that are homologues to their human miRNA counterpart were selected and 1021 
compared to human bone marrow mesenchymal stem cell (BMSC) and dermal 1022 
fibroblast exosome miRNA. Those miRNA also shown to be abundant in BMSC 1023 
exosomes and L cell exosomes in comparison to fibroblast exosomes are displayed 1024 
(B) as mean estimated abundance (derived from the reads) ± SEM. Comparative 1025 
data for miRNA expression in BMSC exosomes/fibroblast exosomes is from a 1026 
previous publication (Mead et al., 2018b). 1027 
Fig. 7. Exosome treatment of human retina. Heterogeneous retinal cultures were 1028 
generated from a human embryonic stem cell line expressing a fluorescent marker 1029 
under the brn3b (retinal ganglion cell (RGC) specific) promoter. To induce RGC 1030 
degeneration, colchicine, a microtubule poison, was added to cultures (B) and led to 1031 
significant RGC loss compared to uninjured controls (A). Ciliary neurotrophic factor 1032 
(CNTF) led to significant neuroprotection of RGC (positive control, C), as did 1033 
mesenchymal stem cell (MSC) exosomes (D), and tumor necrosis factor-α (TNF-α) 1034 
primed MSC exosomes (E; scale bar: 250µm). The quantified number of BRN3B+ 1035 
RGC is shown in F. Fig.2 from Mead et al., 2020 re-used under the Creative 1036 
Commons Attribution 4.0 International (CCBY4.0) licence. 1037 
 1038 
Table 1: The ten most abundant miRNA in exosomes isolated from human 1039 
mesenchymal stem cells (bone marrow-derived mesenchymal stem cells, BMSC; 1040 
umbilical cord blood-derived mesenchymal stem cells, UCMSC; adipose-derived 1041 
stem cells, ADSC). 1042 
Study 


































miR-221-3p miR-1246 miR-143-3p miR-21-5p miR-125b-5p miR-21 miR-21-5p miR-486-5p 
let-7a-5p miR-23a-3p miR-10b-5p miR-125b-5p miR-21-5p miR-125b miR-125b-5p miR-10a-5p 
miR-21-5p miR-451a miR-486-5p miR-221-3p miR-24-5p miR-23a miR-23a-3p miR-10b-5p 
miR-320a miR-125b-5p miR-22-3p miR-16-5p miR-16-5p miR-100 miR-100-5p miR-191-5p 
miR-486-5p miR-199a/b-3p miR-21-5p let-7a-5p miR-92a-3p let-7f-5p miR-145-5p miR-222-3p 
miR-423-5p let-7a-5p miR-222-3p miR-23a-3p miR-100-5p let-7a-5p let-7f-5p miR-22-3p 
miR-21-5p miR-4454/7975 miR-191-5p miR-100-5p miR-106a-5p miR-145 let-7a-5p let-7a-5p 
miR-1246 miR-21-5p miR-100-5p miR-142-3p miR-19b-3p miR-1260b miR-1260a miR-21-5p 
miR-122-5p let-7b-5p let-7a-5p miR-222-3p miR-145-5p miR-1260a miR-1260b miR-127-3p 










• Extracellular vesicles/exosomes are small membrane-bound particles containing mRNA, 
 miRNA and protein 
• Their role in intercellular signalling lends them potential as candidate therapies in the eye 
• EV have demonstrated efficacy in multiple retinal disease models, acting on a variety of cell 
 types and through a variety of mechanisms 
• These mechanisms are still poorly understood, as is the most efficacious EV formulation for 
 any particular retinal disease 
